Mitsubishi Tanabe’s Domestic Remicade Sales Jump 41.2 Percent, Result In Better Performance
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Stable Japanese sales of Mitsubishi Tanabe's rheumatoid arthritis drug Remicade (infliximab) translated to better performance for the April to June quarter, the company reported July 30